progression-free survival

Overview

Progression-free survival (PFS) is the time from the start of treatment until disease progresses or the patient dies of any cause, whichever comes first. It differs from overall survival (OS) in counting progression as an event, which makes it reachable far sooner and with fewer patients — the reason it has become a common primary endpoint in oncology trials and a frequent basis for regulatory approval, particularly where long post-progression survival would make an OS trial impractically large or slow. It is assessed by standardized radiologic criteria, most often RECIST, and is reported alongside objective response rate and duration of response.

Its weaknesses are consequences of how it is measured. Progression is detected only when a scan is performed, so PFS is interval-censored and its apparent value depends on the imaging schedule; unequal or unblinded assessment between arms biases the result, which is why blinded independent central review is used to check investigator assessment. Patients who stop treatment for toxicity and are no longer scanned may be censored informatively, in a manner correlated with the outcome being measured. And because death from any cause counts as an event, PFS is not independent of competing mortality, though it is generally unaffected by therapies given after progression.

The deeper question is what it stands for. PFS is valuable as a direct measure of disease control and of the interval before a patient's cancer worsens, but its correlation with overall survival is inconsistent across tumor types and drug classes, and a statistically significant PFS gain of a few weeks may not correspond to any survival or symptom benefit. This gap is sharpest with checkpoint inhibitor regimens, where delayed separation of curves and pseudo-progression complicate the endpoint further. PFS remains useful for comparing treatment sequencing strategies and identifying prognostic factors, and in lung cancer, renal cell carcinoma, multiple myeloma and other solid tumors it is routinely reported — but as a surrogate for survival it requires validation within each specific setting rather than assumption.

Recent Publications Summary

Recent studies evaluated progression-free survival as a primary or key efficacy endpoint across several disease settings, including systemic anaplastic large cell lymphoma, metastatic renal cell carcinoma, digestive Cancers treated with immunotherapy, unresectable stage IVB hypopharyngeal squamous cell carcinoma, primary CNS lymphoma, newly diagnosed multiple myeloma, advanced non-small cell lung cancer with cachexia, relapsed/refractory multiple myeloma, and metastatic prostate cancer 42584691Aug42527074Jul42498483Jul42498484Jul42486133Jul42444515Jul42411631Jul42342528Jun42223064Jun. These studies used retrospective cohorts, prospective observational designs, randomized phase 3 trials, single-arm phase 2 treatment protocols, and simulation modeling to assess how treatment choice, clinical factors, or treatment sequencing related to disease progression and time to progression-free survival events 42584691Aug42527074Jul42498483Jul42498484Jul42486133Jul42444515Jul42411631Jul42342528Jun42223064Jun.

In systemic anaplastic large cell lymphoma, a multicenter retrospective study developed an individualized three-factor nomogram for predicting progression-free survival based on serum β2-microglobulin elevation, extranodal disease, and front-line chemotherapy choice; internal validation showed strong discrimination with 1-, 3-, and 5-year AUCs of 0.81, 0.85, and 0.87 and a corrected C-index of 0.779 42584691Aug. In metastatic renal cell carcinoma, a Japanese multicenter real-world cohort of 160 patients treated first-line with pembrolizumab plus lenvatinib reported a median progression-free survival of 35 months and used Cox proportional hazards models to explore prognostic factors 42527074Jul. In digestive Cancers with deficient mismatch repair/microsatellite instability-high treated with checkpoint inhibitors, an international multicenter study of 1,175 patients designated the association between grade ≥3 immune-related adverse events and progression-free survival as its primary endpoint, using landmark and time-dependent survival models to account for timing of toxicity 42498483Jul. A prospective phase 2 study in stage IVB hypopharyngeal squamous cell carcinoma used progression-free survival as the primary endpoint for toripalimab plus chemotherapy followed by concurrent chemoradiotherapy with nimotuzumab and toripalimab maintenance; after a median follow-up of 31 months, median PFS was not reached and the 2-year PFS rate was 67.7% 42498484Jul.

Other studies assessed progression-free survival in comparative or real-world treatment analyses. In primary CNS lymphoma, the MATRix/IELSG43 phase 3 trial compared thiotepa-based HCT-ASCT with non-myeloablative R-DeVIC consolidation after MATRix induction, with progression-free survival among the main efficacy outcomes 42486133Jul. In transplant-eligible newly diagnosed multiple myeloma, a real-world study compared daratumumab plus bortezomib, lenalidomide, and dexamethasone with VRd-based therapy and found that the quadruplet regimen was associated with a 63% lower risk of progression or death, with median PFS not reached in either cohort 42444515Jul. In non-small cell lung cancer with cachexia, the SPIRAL-ANA observational study evaluated anamorelin during chemoimmunotherapy against a predefined progression-free survival threshold and reported a median PFS of 6.2 months 42411631Jul. In 4L+ relapsed/refractory multiple myeloma, a Markov simulation model estimated substantially longer median PFS with CAR T-cell therapy followed by bispecific antibodies than with the reverse sequence 42342528Jun. In metastatic prostate cancer harboring homologous recombination repair alterations, an ongoing phase 3 trial identified investigator-assessed imaging-based progression-free survival as the primary endpoint for talazoparib plus enzalutamide versus placebo plus enzalutamide 42223064Jun.

What Changes, What Holds

1. Risk models may sharpen prognosis without changing what PFS means
METHOD Multivariable nomograms and Cox models for anaplastic large cell lymphoma, renal cell carcinoma, and related cohorts refine how progression-free survival is predicted and interpreted in practice, but they do not alter the endpoint itself or its established role as a disease-control measure. The main change is analytic: PFS is being used more often as an input to individualized risk estimation and prognostic modeling rather than only as a trial outcome 42584691Aug42527074Jul.

2. PFS remains a usable endpoint even when toxicity and timing complicate its interpretation
REINFORCES Immune-related adverse events, prolonged follow-up, and prospective use in hypopharyngeal cancer all sit comfortably within the existing account of PFS as a common efficacy endpoint, while also showing how its interpretation depends on censoring, landmarking, and treatment context. The new work does not challenge the baseline concerns about scan timing or assessment bias; instead, it underscores that PFS remains serviceable across immunotherapy-heavy settings and complex multimodality regimens 42498483Jul42498484Jul.

3. Treatment sequencing and comparative strategy can move PFS in either direction
NEW DIRECTION Sequencing questions in myeloma, consolidation choice in primary CNS lymphoma, and investigator-assessed PFS in metastatic prostate cancer extend the baseline by showing PFS being used to compare strategy, not just drugs, and by making it a decision tool for order of therapy. That use was already mentioned in general terms, so the new work mainly sharpens it; the most notable addition is that modeling and real-world comparisons can project large PFS differences even when the Overview does not yet speak to those specific sequences 42486133Jul42342528Jun.

Overview update candidates: individualized prognostic nomograms for PFS; strategy-level use of PFS in treatment sequencing comparisons.